PARIS--(BUSINESS WIRE)--The Ipsen Group (Paris:IPN) has noted that the French Haute Autorité de Santé has recommended to modify the reimbursement policies related to certain medicines, including vasodilatators, the pharmacological class to which Tanakan® belongs. As regards to those medicines used in the treatment of cognitive impairments in the elderly, it considers their withdrawal from the list of reimbursable drugs, which “can however be implemented progressively”.
